Isomorphic Labs prepares to launch trials for AI-designed drugs
Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview …
Post
-
-
PYC Therapeutics to begin Part B in SAD trial for polycystic kidney disease
PYC Therapeutics is set to begin Part B in its single ascending dose (SAD) study of the drug candidate, PYC-003, …
-
FDA and EMA authorise AB Science’s Phase III trial of prostate cancer treatment
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have authorised AB Science’s confirmatory Phase III …
-
Judge orders FDA to reinstate clinical trial diversity webpages
A court has ordered several US government agencies, including the US Food and Drug Administration (FDA), to restore healthcare resources …
-
Vertex reports long-term results for Casgevy in sickle cell and thalassaemia
Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) patients for 5.5 years and …
-
Headlands Research acquires Puerto Rico’s clinical research site
Headlands Research has acquired Puerto Rico’s clinical research site, CMRCenter (CMRC), for an undisclosed sum. This strategic move broadens Headlands' reach …
-
Novartis’ Cosentyx shows no benefit in Phase III GCA trial
Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or …
-
China’s NMPA approves initiation of InnoCare’s trial of B7-H3 targeted ADC
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted approval to the investigational new drug …
-
BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma
BioAtla has presented first-in-human Phase I study data of its anti-cancer therapy, BA3182, targeting those with treatment-refractory metastatic adenocarcinoma. The findings …
-
Study finds UK leads Europe in clinical trial set-up speed
A study conducted by investigators across Europe has found that the UK had shorter clinical trial approval and set-up times …
-
Housing First intervention associated with reduced opioid overdoses
Opioid use disorder (OUD) has become a mounting public health crisis in the US, often disproportionately affecting individuals in the …
-
Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy
Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant …
-
UK Government reveals 10-year plan for NHS
The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community …
-
Organon discontinues endometriosis drug after Phase II flunk
Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept …
-
Ascletis begins dosing in Phase IIa trial of ASC30 for obesity treatment
Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30. …
